Enlicitide Adds an Oral Option for Hypercholesterolemia
Episode Summary
Enlicitide is the first oral PCSK9 inhibitor approved for additional LDL-C lowering, offering a convenient option for adults with persistent hypercholesterolemia despite maximally tolerated statins.